Yingxin Xu - Regeneron Pharmaceuticals, Inc

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 41 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis with Nasal Polyposis: an Indirect Treatment Comparison

Claire Hopkins,Joseph K. Han,Wytske Fokkens,Martin Wagenmann,Patricia Guyot,Asif H. Khan,Scott Nash,Zhixiao Wang,Yingxin Xu,Jérôme Msihid, Binod Neupane,Arpita Nag,Claus Bachert

The Journal of Allergy and Clinical Immunology In Practice (2024)

引用0浏览0WOS引用

Dupilumab Demonstrates Higher Likelihood of Achieving Improvements in Signs, Symptoms, and Quality of Life Vs Lebrikizumab: Results from a Placebo-Adjusted Indirect Comparison Analysis

Patricia Guyot,Yingxin Xu,Amy Praestgaard,Nick Freemantle,Ana B. Rossi,Brad Shumel,Gaelle Bego Le Bagousse,Zhixiao Wang, Kerry Noonan,Mike Bastian

BRITISH JOURNAL OF DERMATOLOGY (2024)

引用0浏览0引用

P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM)

Jeffrey Zonder,Hans Lee,Joshua Richter,Naresh Bumma,Zheng-Yi Zhou,Viviana Garcia-Horton,Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Wenxin Ma,Qiufei Ma,Timothy Inocencio,Yingxin Xu, Evelien Bergrath,James Harnett,Tito Roccia,Glenn S. Kroog,Karen Rodriguez Lorenc,Yariv Houvras,Sundar Jagannath

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S267-S267

引用0浏览0引用

P-402 Indirect Comparison of Linvoseltamab Versus Teclistamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): an Updated Analysis Based on 14-Month Follow-Up Data

Hans Lee,Naresh Bumma,Joshua Richter,Jeffrey Zonder,James E. Hoffman,Zheng-Yi Zhou,Viviana Garcia-Horton,Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Wenxin Ma,Qiufei Ma,Timothy Inocencio,Yingxin Xu, Evelien Bergrath,James Harnett,Tito Roccia,Glenn S. Kroog,Karen Rodriguez Lorenc,Yariv Houvras

Clinical Lymphoma Myeloma and Leukemia (2024): S266-S267

引用0浏览0引用

Dupilumab Demonstrates Higher Likelihood of Maintaining Efficacy Outcomes Compared with Lebrikizumab in Monotherapy at Week 52: Results from a Placebo-Adjusted Indirect Comparison Analysis

Patricia Guyot,Yingxin Xu,Amy Praestgaard,Nick Freemantle,Ana B. Rossi,Brad Shumel,Gaelle Bego-Le-Bagousse,Zhixiao Wang, Kerry Noonan,Mike Bastian

BRITISH JOURNAL OF DERMATOLOGY (2024)

引用0浏览0引用

Indirect Comparison of Linvoseltamab Versus Teclistamab for Triple-Class Exposed (TCE) Relapsed/refractory Multiple Myeloma (RRMM)

Joshua Richter,Sundar Jagannath,Hans Lee,James E. Hoffman,Jeffrey Zonder,Zheng-Yi Zhou,Viviana Garcia-Horton,Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Wenxin Ma,Qiufei Ma,Timothy Inocencio,Yingxin Xu, Evelien Bergrath,James Harnett,Tito Roccia,Glenn S. Kroog,Karen Rodriguez Lorenc,Yariv Houvras,Naresh Bumma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S274-S275

引用0浏览0引用

Impact of the Treatment Crossover Design on Comparative Efficacy in EMPOWER-Lung 1: Cemiplimab Monotherapy As First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Josephine Louella Feliciano,Dylan McLoone,Yingxin Xu,Ruben G. W. Quek,Andreas Kuznik,Jean-Francois Pouliot,Giuseppe Gullo,Petra Rietschel,Patricia Guyot,Gerasimos Konidaris,Keith Chan,Sam Keeping,Florence R. Wilson,Nick Freemantle

FRONTIERS IN ONCOLOGY (2023)

引用3浏览0WOS引用

Pairwise Indirect Treatment Comparison of Dupilumab Versus Other Biologics in Patients with Uncontrolled Persistent Asthma

Eric D. Bateman,Asif H. Khan,Yingxin Xu,Patricia Guyot,Jingdong Chao,Siddhesh Kamat,Paul Rowe,Heather Burnett,Jerome Msihid,David Weinreich,Ian D. Pavord

Respiratory medicine（2022）

引用1浏览0引用

Network Meta-Analysis of Immune-Oncology Monotherapy As First-Line Treatment for Advanced Non-Small-cell Lung Cancer in Patients with PD-L1 Expression ⩾50%

Nick Freemantle,Yingxin Xu,Florence R. Wilson,Patricia Guyot,Chieh- Chen,Sam Keeping,Gerasimos Konidaris,Keith Chan,Andreas Kuznik,Kokuvi Atsou,Emily Glowienka,Jean-Francois Pouliot,Giuseppe Gullo,Petra Rietschel

Therapeutic Advances in Medical Oncology（2022）

引用2浏览0WOS引用

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression >= 50% (vol 14, pg 1, 2022)

N. Freemantle,Y. Xu,F. R. Wilson

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn